Exploring the Association between Obesity, Inflammation, and Type II Diabetes: Insights from Body Mass Index Correlation and Immune Response Analysis
DOI:
https://doi.org/10.22401/p230yy05Keywords:
T2D, BMI , IAA, ANAAbstract
Diabetes mellitus (DM) is a group of physiological disorders characterized by a prolonged hyperglycemic state caused by insulin secretion and activity. Recently, several study positive correlations between the increase in BMI and T2D. Additionally, the immune system has contributed to the pathogenicity of T2D in obese individuals. The current study sought to investigate the correlation between obesity and inflammation in obese T2D and obese non-T2D individuals and also detected the role of increasing BMI in obese individuals and developing T2D. The finding involved 100 participants (50 obeseT2D and 50 obese without T2D). The serum of all participants underwent the following immunological and biochemistry tests, which include FBS, Insulin, IAA, ANA, BMI, and HOMA-IR. This study revealed that obese males develop T2D more than females (60.0%, 40.0% respectively) Moreover, Obese T2D and obese without T2D individuals were increased concentrations of IgG in serum levels with markers (ANA, HOMA-IR, and IL-6). While IgG levels in IAA serum were considerably greater in obese T2D individuals only. Furthermore, BMI has been positively associated with an increasing level of ANA, HOMA-IR, and IL-6 in both groups. This investigation unveiled a direct correlation between escalating BMI and the incidence of T2D. Additionally, it revealed the active impact of obesity on the immune response and its consequential contribution to the pathogenesis of T2D.
References
Yedjou, C.G.; Grigsby J.; “The Management of Diabetes Mellitus Using Medicinal Plants and Vitamins”. J Mol Sci, 24 (10): 9085-9089, 2023.
Tomic, D.; Shaw, J.E.; “The burden and risks of emerging complications of diabetes mellitus”. Nat. Rev. Endocrinol, 18(9), 525-539, 2022.
Sundharan, Z.I.; Ramchandran, D.M.; “Dyslipidemia in Prediabetes Population: A Retrospective Study of 91780 Cases”. Int .J .Health .Sci .Res, 12 (10): 132–139, 2022.
Cloete, L.; “Diabetes Mellitus: An Overview of the Types, Symptoms, Complications and Management”. Nurs Stand, 37 (1):61–66, 2021.
Rohm, T.V.; Meier, D.T.; Olefsky, J.M.; “Inflammation in obesity, diabetes, and related disorders”. Immunity, 55(1): 31-55, 2022.
Chiu, H.K.; Tsai, E.C.; Juneja, R.; “Equivalent Insulin Resistance in Latent Autoimmune Diabetes in Adults (LADA) and Type 2 Diabetic Patients”. Diabetes Res. Clin. Pract. 77 (2):237–244, 2007.
Liberal, R.; Grant, C.R.; Longhi, M.S.; “Diagnostic Criteria of Autoimmune Hepatitis”. Autoimmun Rev, 13 (5): 435–440, 2014.
Mahmud, S.A.; Binstadt, B.A.; “Autoantibodies in the Pathogenesis, Diagnosis, and Prognosis of Juvenile Idiopathic Arthritis”. Front. Immunol. 9 (5):22-29, 2019.
Carbone, F.; La Rocca, C.; De Candia, P.; “Metabolic Control of Immune Tolerance in Health and Autoimmunity”. Autoimmun Rev, 28 (5): 491–504, 2016.
Lutz, T.A.; “Mammalian Models of Diabetes Mellitus, with a Focus on Type 2 Diabetes Mellitus”.Nat. Rev. Endocrinol, 3(22):12-19, 2023.
Macartney-Coxson, D.; Benton, M. C.; Blick, R.; “Genome-Wide DNA Methylation Analysis Reveals Loci That Distinguish Different Types of Adipose Tissue in Obese Individuals”. J. Clin. Epigenet, 9 (1):12-20, 2017.
Maurya, R.; Bhattacharya, P.; Dey, R.; “Leptin Functions in Infectious Diseases”. Front. Immunol, 9 (2):55-61, 2018.
Al-Badri, A.S.; Noori, E.; Ajah, H.; “Assessments frequency of oral fungal infection with type 2 diabetes mellitus in Iraqi patients”. Academicia Globe: Inderscience Res, 3 (1): 111–118, 2022.
Abbas, A; Nassar, G.; Haider A; Hussein, A.; “Prevalence and Correlation of Glycemic Control Achievement in Patients with Type 2 Diabetes in Iraq: A Retrospective Analysis of a Tertiary Care Database over a 9-Year Period”. Clin Res Rev, 14 (3): 265–272, 2020.
Kazeminia, M.; Salari, N.; Mohammadi, M.; “Prevalence of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in Iran: A Systematic Review and Meta-Analysis”. J. Diabetes Res, 15 (5): 1–9, 2020.
Al Mansour, M.A.; “The Prevalence and Risk Factors of Type 2 Diabetes Mellitus (DMT2) in a Semi-Urban Saudi Population”. IJERPH, 17 (1): 7-15, 2019.
Meier, H.C.; Sandler, D.P.; Simonsick, E.M.; Weng, N.; “Sex Differences in the Association between Antinuclear Antibody Positivity with Diabetes and Multimorbidity in Older Adults: Results from the Baltimore Longitudinal Study of Aging”. Exp. Gerontol. 35 (5): 110-120, 2020.
Al-Badri, A.S.; Ali, E.N.; Ajah, A.; “Effect of IL-23 Receptor Gene Polymorphism (Rs1884444) on the Prevalence of Oral Fungal Infection in Patients 0with Type 2 Diabetes Mellitus: A Case-Control Study in Iraqi Patients”. Clin Res Rev, 77 (5): 1553–1560, 2022.
Kadhim, A.S.; “The Significance of Genetic Polymorphism for IL-17Agene (Rs 3819024) A/G in Iraqi Arab Patients with Type II Diabetes Mellitus (T2DM)”. BBRC, 14 (7): 201–204, 2021.
Ebrahimi, S.; Hosseini, M.; Shahidsales, S.; “Targeting the Akt/PI3K Signaling Pathway as a Potential Therapeutic Strategy for the Treatment of Pancreatic Cancer”. Curr. Med. Chem., 24 (13): 1321–1331, 2017.
Berbudi, A.; Rahmadika, N.; Cahyadi, A.I.; “Type 2 Diabetes and Its Impact on the Immune System”. Curr. Diabetes Rev, 16 (5): 442–449, 2020.
Hershman, D.L.; Till, C.; Wright, J.D.; “Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials”.J Clin Oncol, 34 (25): 3014–3022,2016.
Lovic, D.; Piperidou, A.; Zografou, I.; Grassos, H.; “The Growing Epidemic of Diabetes Mellitus”. Curr. Vasc. Pharmacol , 17 (2): 22-33,2019.
Losada-Barragán, M.; “Physiological Effects of Nutrients on Insulin Release by Pancreatic Beta Cells”. Mol. Cell. Biochem, 1 (2):12-16, 2021.
Amer, A.S.; Othman, A.A.; Dawood, L.M.; “The Interaction of Schistosoma Mansoni Infection with Diabetes Mellitus and Obesity in Mice”. Sci Rep, 13 (1): 9417-9422, 2023.
Mizuki, Y.; Sakamoto, S.; Okahisa, Y.; “Mechanisms Underlying the Comorbidity of Schizophrenia and Type 2 Diabetes Mellitus”. J. Neuropsychopharmacol, 24 (5):60-66, 2020.
Šimonienė, D.; Stukas, D.; Daukša, A.; Veličkienė, D.; “Clinical Role of Serum MiR107 in Type 2 Diabetes and Related Risk Factors”. Biomolecules, 12 (4): 558-560, 2022.
Liu, L.; Ruan, Z.; Ung, C.O.L.; “Long-Term Cost-Effectiveness of Subcutaneous Once-Weekly Semaglutide versus Polyethylene Glycol Loxenatide for Treatment of Type 2 Diabetes Mellitus in China”. Diabetes Ther, 14 (1): 93–107, 2022.
Song, Y.; Wu, Z.; Zhao, P.; “The Function of Metformin in Aging-Related Musculoskeletal Disorders. Front. Pharmacol, 13 (2):15-20, 2022.
Zheng, H.; Sun, W.; Zhang, Q.; “Proinflammatory Cytokines Predict the Incidence of Diabetic Peripheral Neuropathy over 5 Years in Chinese Type 2 Diabetes Patients: A Prospective Cohort Study”. Clin Med, 31 (2):12-19, 2021.
Guest, C. B.; Park, M. J.; Johnson, D. R.; “The implication of proinflammatory cytokines in type 2 diabetes”. Front Biosci. 13(1): 5187-94,2018.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Hawraa I. Kadhim, Ali Saad Kadhim
This work is licensed under a Creative Commons Attribution 4.0 International License.
.jpg)
